Singapore markets closed

Collegium Pharmaceutical, Inc. (COLL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
38.82-2.09 (-5.11%)
At close: 04:00PM EDT
38.79 -0.03 (-0.08%)
After hours: 04:29PM EDT

Collegium Pharmaceutical, Inc.

100 Technology Center Drive
Suite 300
Stoughton, MA 02072
United States
781 713 3699
https://www.collegiumpharma.com

Sector(s)Healthcare
IndustryDrug Manufacturers - Specialty & Generic
Full-time employees197

Key executives

NameTitlePayExercisedYear born
Mr. Michael Thomas Heffernan B.S. Pharm, R.Ph.Co-Founder & Chairman110kN/A1964
Mr. Joseph J. CiaffoniPresident, CEO & Director1.69M516.5k1972
Ms. Colleen TupperExecutive VP & CFO848.29kN/A1976
Ms. Shirley R. KuhlmannExecutive VP, General Counsel, Chief Administrative Officer & Secretary842.9kN/A1984
Mr. Scott DreyerExecutive VP & Chief Commercial Officer746.58kN/A1972
Dr. Thomas B. Smith FAAFP, M.D.Executive VP & Chief Medical Officer692.91kN/A1961
Dr. Christopher Shayne James M.D.Vice President of Investor RelationsN/AN/AN/A
Mr. Bart J. DunnExecutive Vice President of Strategy & Corporate DevelopmentN/AN/AN/A
Mr. Scott SudduthHead of Technical OperationsN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Corporate governance

Collegium Pharmaceutical, Inc.’s ISS governance QualityScore as of 1 March 2024 is 3. The pillar scores are Audit: 9; Board: 4; Shareholder rights: 2; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.